Treatment outcome according to tumour RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab.

If you would like to view this content you will need to register
(You will need your Username or E-mail along with your Password)
Click here to register or if you have forgotten your password.